May 2026 Research Update

Across these papers, diagnosis and monitoring of Langerhans cell histiocytosis (LCH) relied on combining imaging with tissue testing. Scans helped locate and track lesions (bone, thyroid, and pituitary area), while biopsy or needle sampling plus special lab stains helped confirm LCH and distinguish it from other diseases that can look similar. [1] [2] [3] [4]

In one infant with a single thigh bone lesion, multiple scans (X-ray, MRI, and a whole-body PET-CT) were used to show the problem was limited to one bone site, and a biopsy confirmed LCH using common LCH markers (S100 and CD1a). Follow-up imaging showed no progression in the short term in this one patient. [1]

In one adult with multisystem disease, thyroid ultrasound showed irregular darker areas with little internal blood flow, and a fine-needle sample was examined under the microscope and confirmed with LCH markers (CD1a and Langerin). This illustrates how thyroid involvement can be evaluated without a larger surgical biopsy in some situations. [2]

For pituitary stalk thickening in children, one center reported that repeated MRI scans over time helped identify which patients changed enough to justify biopsy: 5 of 18 progressed and were biopsied, and 2 of those biopsies showed LCH (while others showed different diagnoses). Many patients stayed stable on MRI, and some had complete resolution, showing why monitoring over time can matter when the cause is not clear at the start. [3]

One additional case description focused on the range of pituitary MRI appearances in a teenager with central diabetes insipidus, noting imaging features that can raise suspicion for LCH. This supports the idea that pituitary MRI patterns may suggest LCH, even though imaging alone may not be definitive. [4]

For patients and caregivers, these reports reinforce that LCH diagnosis is often a step-by-step process: scans help show where disease may be and whether it is in one place or multiple places, while lab testing of a tissue or needle sample is commonly used to confirm LCH and rule out other causes. The monitoring studies also show that when the pituitary area is involved, repeat MRI over months can clarify whether a lesion stays stable, improves, or progresses, but the exact best schedule and which changes always require biopsy remain uncertain from these single-center and case-based reports. [1] [2] [3] [4]

Two papers looked at newer ways to support diagnosis or follow-up beyond routine imaging and standard pathology. One focused on tracking a known gene change in blood during treatment, and another used computer-based analysis of pituitary MRI to help distinguish LCH from a tumor that can look similar in the same area. Both were exploratory and not yet proven for broad, routine use. [5] [6]

In a small retrospective cohort of 11 children treated with trametinib, clinicians used HistioTrak, a droplet digital PCR blood test designed to detect the BRAF V600E change in blood cells, as a way to monitor minimal residual disease. The test found BRAF V600E in 5 of 11 patients, and some patients shifted between positive and negative over time, showing that repeated blood testing was feasible in selected cases. [5]

In a retrospective study of 93 children with sellar-region lesions, researchers trained machine-learning models using measurements taken from standard MRI sequences (T1 and T2) plus clinical and imaging features to separate LCH from tumor-marker-negative sellar germ cell tumors. The best combined model reached an AUC of 0.81 on an independent test set, suggesting it could potentially support decision-making when the diagnosis is unclear, though the authors noted limits like single-center data and no external validation. [6]

A small pathology study compared Langerhans cell histiocytosis (LCH) with the rarer and more aggressive Langerhans cell sarcoma (LCS) using specialized protein staining and gene testing. The study reported different patterns of ASPP2 and iASPP staining between LCS and LCH, and found a MAP2K1 mutation in 4 of 6 LCS samples, suggesting potential laboratory clues that may help pathologists tell these conditions apart in difficult cases. [7]

These studies mainly matter as background research that could refine how LCH is confirmed and tracked in the future. Blood-based monitoring only applies to people whose LCH carries the specific BRAF V600E change that the test targets, and the MRI computer models and specialized pathology markers still need testing in larger, multi-center groups to show they work reliably across hospitals and scanners. For now, the uncertainty is how well these tools predict disease activity compared with standard follow-up methods in everyday care. [5] [6] [7]

Across these studies in children, relapse or progression risk was higher when disease looked more widespread or intense at the start, such as fever at diagnosis, multisystem involvement (especially when certain higher-risk organs were involved), and multiple bone lesions. Some predictors were simple clinical features (like fever), while others were measurements from blood markers or a whole-body scan. Overall survival was high in the prospective bone-only study, but event-free survival (staying free of relapse/progression) varied based on disease extent and where lesions were located. [8] [9] [10]

In a large single-center study, children who had fever at diagnosis tended to be younger and had more organ involvement and higher levels of inflammatory blood markers and a blood-based BRAF V600E signal. After first-line therapy, the fever group had much lower 3-year progression-free survival than children without fever, meaning early treatment was less likely to keep the disease controlled. In that analysis, fever remained an independent predictor of worse first-line outcomes along with factors such as risk-organ involvement, skin involvement, ferritin, and changes in the erythrocyte sedimentation rate (a blood inflammation marker). [8]

In the prospective international pilot trial of children with single-system bone disease treated for six months, having multiple bone lesions was the strongest predictor of relapse, with lower 5-year event-free survival than in children without multiple bone lesions. In contrast, certain higher-risk bone locations did not independently lower event-free survival, but they did increase the chance of developing central diabetes insipidus over time, especially when combined with multiple bone lesions. This highlights that relapse risk and long-term complication risk may come from different aspects of the disease. [9]

In a smaller retrospective study using a whole-body sugar-uptake scan (18F-FDG PET-CT), children with single-system disease had better long-term event-free and overall survival than those with multisystem disease, and multisystem disease involving risk organs had the worst outcomes. The study also found that the baseline scan measure (SUVmax) was higher in children who later died than in those who survived, suggesting that stronger scan activity at diagnosis may relate to more severe disease. Because this was a small, retrospective study, the scan result needs cautious interpretation. [10]

For families, these results help explain why doctors may talk about prognosis in terms of how widespread the disease is (single-system vs multisystem), whether higher-risk organs are involved, whether bone disease is in one spot or many, and whether there are strong inflammation signs like fever at diagnosis. Some factors appear to predict relapse/progression (fever, multiple bone lesions, risk-organ involvement), while certain lesion locations may be more about the risk of lasting endocrine effects like central diabetes insipidus. What remains uncertain is how well scan-based measures like SUVmax or specific blood signals apply across different hospitals and treatment approaches, since some evidence here came from retrospective, single-center experiences. [8] [9] [10]

Across this group of papers, the strongest evidence came from a small phase II trial in children with Langerhans cell histiocytosis (LCH) that had returned or not responded to earlier treatment, showing many patients improved on clofarabine but most had severe side effects. The other papers were individual case reports in adults, describing long-lasting control or partial improvement with different drug approaches chosen for that persons disease pattern and test results. [11] [12] [13] [14]

In a prospective, multicenter phase II study of children with recurrent or refractory LCH, 85% responded to clofarabine after two treatment cycles. At 2 years, progression-free survival was 89% and overall survival was 100% in the LCH group, but 80% of participants had grade 3 or higher toxicities (serious side effects). [11]

One adult with multisystem LCH (bone and pituitary involvement) had durable disease control for 70 months while treated with vinblastine and prednisolone along with zoledronic acid for bone disease, and the main reported treatment-related problem was mild nerve symptoms. This is a single-patient report, so it cannot show how often others would have the same result. [12]

Two case reports focused on targeted treatments guided by genetic testing. A patient with mixed LCH and Erdheim-Chester disease had a partial clinical and lab response to trametinib (along with desmopressin for diabetes insipidus), and another patient with skin-limited BRAF V600E-positive LCH and chronic myelomonocytic leukemia responded to dabrafenib with the BRAF signal in circulating DNA becoming undetectable. Both reports describe one person each and do not prove how well these approaches work in larger groups. [13] [14]

For patients and caregivers, this set of papers mainly adds two kinds of information: (1) clofarabine has trial-level evidence in children with LCH that has come back or not responded, showing frequent responses but also frequent serious side effects, and (2) in select adult situations, doctors sometimes use treatments based on disease pattern and mutation testing, but the evidence here is limited to single-person reports. What remains uncertain is how these different drug options compare with each other, which patients benefit most, and how durable responses are outside of small studies and case reports.

Across these papers, bone and pain management in Langerhans cell histiocytosis (LCH) centered on two practical needs: relieving pain from active bone lesions and addressing destructive jaw or facial bone disease with accurate diagnosis and coordinated care. Evidence ranged from a small retrospective series for a bone-targeting medicine to individual case reports for jaw involvement, so results should be interpreted cautiously. [15] [16] [17]

In a retrospective single-center series of eight children with bone LCH, intravenous zoledronate was followed by rapid pain improvement in all four children who had pain symptoms, with a median time to improvement of 18 days. On follow-up X-rays, all eight children with imaging follow-up had either complete lesion resolution (2 children) or radiographic improvement (6 children). [15]

Side effects in the zoledronate series were limited in this small group: four children had transient fever, and the report noted no symptomatic low calcium levels and no osteonecrosis of the jaw. The authors also described that baseline vitamin D and calcium levels were adequate in their patients, and they noted limits such as small sample size and mixed prior or concurrent therapies. [15]

Two case reports focused on jaw or facial bone involvement, showing how LCH can appear as destructive osteolytic jaw lesions with oral symptoms and pain, and that biopsy with immunohistochemistry can confirm the diagnosis. One 3-year-old had bilateral jaw bone loss with gingival ulcers and jaw pain, with biopsy showing S100 and CD1a-positive histiocytes with eosinophils. [17]

In another single-patient report, a 5-year-old boy had facial swelling and destructive maxillary (upper jaw) bone lesions; magnetic resonance imaging (MRI) and tissue testing supported LCH, and management included surgical resection plus postoperative chemotherapy (vincristine or vindesine). This illustrates that when LCH affects the jaw and nearby structures, care may involve both local procedures and systemic treatment, depending on the situation. [16]

For patients and caregivers, these studies mainly add background about the range of approaches used for painful bone lesions and for jaw or facial bone disease in children with LCH. Zoledronate was linked to quick pain relief and improved X-ray appearance in a very small, single-center experience, but it is not clear how well these results apply to other hospitals, other age groups, or different patterns of LCH. The jaw case reports underline that mouth sores, jaw pain, facial swelling, or tooth-related changes can be part of LCH and may require tissue confirmation and coordinated treatment decisions; however, case reports cannot predict what will happen for most patients.

Across two case reports (each describing one patient), pulmonary Langerhans cell histiocytosis (lung LCH) appeared in unusual ways that could be mistaken for other serious lung problems, including cancer spread and large airway-blocking lesions. In both reports, a tissue biopsy with specific marker testing confirmed the diagnosis. Over follow-up, lung findings improved, including symptom relief after smoking cessation in one case, but these individual outcomes may not apply to everyone. [18] [19]

In a 72-year-old woman who previously had lung adenocarcinoma surgery, new rib and lung lesions raised concern for metastasis, but a percutaneous biopsy supported lung LCH based on CD1a, Langerin, and S-100 staining. Genetic testing of the lung LCH tissue found a BRAF V600E mutation, and the lesions gradually improved and partly disappeared during long-term follow-up with symptomatic treatment. This report highlights that lung LCH can occur alongside lung cancer and may be difficult to separate from cancer-related changes without biopsy. [18]

In a 36-year-old man, lung LCH presented as multiple obstructing bronchial lesions and large lung masses seen on CT and PET/CT imaging, with symptoms including coughing, coughing up blood, and shortness of breath. An endobronchial biopsy confirmed LCH with characteristic immunohistochemical markers (including CD1a and Langerin). After he quit smoking and did not take drug therapy, his coughing up blood and shortness of breath improved, and at 1 year 9 months he reported no coughing up blood or shortness of breath (with intermittent cough). [19]

For patients and caregivers, these reports mainly add background about how lung LCH can look on scans and why biopsy-based testing is sometimes needed to distinguish it from other lung diseases, including cancer. They also show that some people may have symptom improvement over time, including one patient who improved after stopping smoking, but single-patient reports cannot predict what will happen for most people. Larger studies are still needed to clarify how often these patterns occur and which factors best predict improvement or long-term stability.

Taken together, these papers highlight that Langerhans cell histiocytosis (LCH) can affect ear and skull areas often enough to cause noticeable ear, hearing, and balance problems. Evidence is strongest from a pooled review in children, while detailed hearing-related complications are illustrated by a single-patient report, so how often rapid inner-ear bone changes happen is still uncertain. [20] [21]

In a systematic review and meta-analysis of 20 studies including 885 pediatric patients with head and neck LCH, skull involvement was the most common head and neck site. Otologic (ear) involvement occurred in about 37% of patients, and ear drainage (otorrhea) was a common presenting symptom. [20]

In the same review, systemic chemotherapy was the most commonly used treatment approach, with overall remission reported in 55.2% of patients. Recurrence was reported in 20% of patients, and mortality attributed to LCH was 11.5% in the pooled data. [20]

A separate case report described one 21-year-old man with LCH affecting the temporal bone who developed progressive cochlear ossification (bone formation in the inner ear) along with progressive bilateral hearing loss, tinnitus, vertigo, and imbalance. Repeat CT imaging showed progressive cochlear ossification, which affected cochlear implantation: the first (left) implant had full electrode insertion, while the second (right) implant 4 months later had limited insertion due to more advanced ossification. [21]

For patients and caregivers, this group of studies mainly adds context about what ear, hearing, and skull involvement can look like in LCH, especially in children, and shows one example of how quickly inner-ear changes may progress in temporal bone disease. The clearest near-term takeaway is awareness that ear symptoms (including drainage) are reported often in pediatric head and neck LCH, while questions remain about how frequently rapid cochlear ossification occurs and which patients are most likely to experience it. [20] [21]

This study focused on whether a specific measurement on computed tomography (CT) scans could help separate malignant lacrimal (tear system) tumors from non-cancer causes of similar symptoms. The overall pattern was that malignant tumors showed greater expansion of the bony nasolacrimal duct compared with benign masses and with one-sided primary acquired nasolacrimal duct obstruction (a non-cancer blockage). [22]

In this retrospective imaging study, the median expansion ratio of the bony nasolacrimal duct (affected side compared with the unaffected side) was 167.5% for malignant lacrimal tumors, 123.3% for benign masses, and 106.8% for unilateral obstruction without a mass. The authors suggested that an expansion ratio of 150% or higher may help identify malignant lacrimal tumors among patients with one-sided tear drainage problems. [22]

For patients, this is background research about diagnosis: it suggests one way CT measurements might help doctors judge whether a one-sided tear-duct problem could be due to a tumor rather than a benign blockage. Because this was a single-center retrospective study and focused on imaging measurements, it does not by itself determine what any one person has, and it does not address outcomes after diagnosis. [22]

Across these papers, the common message is that Langerhans cell histiocytosis can overlap with other serious blood and immune complications in children, and outcomes may depend on how completely the complication comes under control. The strongest evidence here comes from one single-center hospital study, while the other report describes a single patient and may not apply to most families.

In a retrospective study of 44 children with cancer-related hemophagocytic lymphohistiocytosis (a dangerous, body-wide overactivation of the immune system), about two-thirds responded to treatment by the end of follow-up. Survival at 1 year was 69.0%, and children who reached complete remission of hemophagocytic lymphohistiocytosis had better overall survival, especially when the syndrome appeared at the time the cancer was first diagnosed. [23]

The same study reported several features linked to worse survival: ferritin over 5000 ng/mL, age over 10 years, and lactate dehydrogenase (LDH) over 500 U/L. It also reported that combining chemotherapy with a stem cell transplant did not show a survival advantage compared with chemotherapy alone in this group. [23]

One case report described a 15-year-old boy with Langerhans cell histiocytosis who later developed chronic myeloid leukemia, identified by the BCR-ABL1 p210 fusion. With imatinib plus cladribine, he reached complete blood count recovery and deep molecular remission of both conditions within 7 months. [24]

For families affected by Langerhans cell histiocytosis, this set of papers is mainly about rare but serious overlaps: a severe inflammation syndrome linked to cancers, and (in one patient) a second blood cancer during the disease course. The cohort study suggests that reaching full control of the inflammation syndrome is closely tied to better survival, and it highlights blood test levels that tracked with risk, but it cannot prove what treatment choices are best because it was retrospective and from one center. The case report shows what was possible for one teenager with two conditions at once, but it does not tell how often this happens or whether the same approach will work for others.